Tags

Type your tag names separated by a space and hit enter

Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Alzheimers Dement. 2014 Oct; 10(5 Suppl):S395-9.AD

Abstract

Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).

Authors+Show Affiliations

Pharmacology and Clinical Evaluation Division, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain. Electronic address: acortesb_autonomo@aemps.es.Pharmacology and Clinical Evaluation Division, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.Nuclear Medicine Department, idcsalud Hospital Albacete, Albacete, Spain.Clinical Biostatistics Department, Hospital Ramón y Cajal, Madrid, Spain.Neurology Department, Hospital Ruber Internacional, Madrid, Spain.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24418060

Citation

Cortes-Blanco, Anabel, et al. "Florbetapir (18F) for Brain Amyloid Positron Emission Tomography: Highlights On the European Marketing Approval." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 10, no. 5 Suppl, 2014, pp. S395-9.
Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, et al. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Alzheimers Dement. 2014;10(5 Suppl):S395-9.
Cortes-Blanco, A., Prieto-Yerro, C., Martinez-Lazaro, R., Zamora, J., Jiménez-Huete, A., Haberkamp, M., Pohly, J., Enzmann, H., Zinserling, J., Strassmann, V., & Broich, K. (2014). Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 10(5 Suppl), S395-9. https://doi.org/10.1016/j.jalz.2013.09.007
Cortes-Blanco A, et al. Florbetapir (18F) for Brain Amyloid Positron Emission Tomography: Highlights On the European Marketing Approval. Alzheimers Dement. 2014;10(5 Suppl):S395-9. PubMed PMID: 24418060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. AU - Cortes-Blanco,Anabel, AU - Prieto-Yerro,Concha, AU - Martinez-Lazaro,Raul, AU - Zamora,Javier, AU - Jiménez-Huete,Adolfo, AU - Haberkamp,Marion, AU - Pohly,Johannes, AU - Enzmann,Harald, AU - Zinserling,Jörg, AU - Strassmann,Valerie, AU - Broich,Karl, Y1 - 2014/01/10/ PY - 2013/06/18/received PY - 2013/09/16/accepted PY - 2014/1/15/entrez PY - 2014/1/15/pubmed PY - 2015/7/15/medline KW - Brain KW - European Medicines Agency KW - Florbetapir ((18)F) KW - Marketing approval KW - Positron emission tomography KW - β-Amyloid SP - S395 EP - 9 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 10 IS - 5 Suppl N2 - Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F). SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/24418060/Florbetapir__18F__for_brain_amyloid_positron_emission_tomography:_highlights_on_the_European_marketing_approval_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1552-5260(13)02842-2 DB - PRIME DP - Unbound Medicine ER -